gptkbp:instanceOf
|
antidepressant
|
gptkbp:approvalYear
|
1964
|
gptkbp:approvedBy
|
gptkb:FDA
|
gptkbp:ATCCode
|
N06AA10
|
gptkbp:brand
|
gptkb:Aventyl
gptkb:Pamelor
|
gptkbp:CASNumber
|
72-69-5
|
gptkbp:category
|
analgesic
antidepressant
norepinephrine reuptake inhibitor
secondary amine
|
gptkbp:chemicalFormula
|
C19H21N
|
gptkbp:contraindication
|
recent myocardial infarction
concurrent MAOI use
|
gptkbp:discoveredBy
|
gptkb:Geigy
|
gptkbp:eliminationHalfLife
|
18–44 hours
|
gptkbp:excretion
|
urine
|
https://www.w3.org/2000/01/rdf-schema#label
|
nortriptyline
|
gptkbp:IUPACName
|
3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methylpropan-1-amine
|
gptkbp:KEGGID
|
D08206
|
gptkbp:legalStatus
|
prescription only
|
gptkbp:mechanismOfAction
|
norepinephrine reuptake inhibitor
serotonin reuptake inhibitor (weak)
|
gptkbp:meltingPoint
|
97–98°C
|
gptkbp:metabolism
|
liver
|
gptkbp:pregnancyCategory
|
C (US)
|
gptkbp:proteinBinding
|
93%
|
gptkbp:PubChem_CID
|
4543
4387
DB00540
CHEMBL1408
|
gptkbp:relatedTo
|
gptkb:desipramine
gptkb:amitriptyline
|
gptkbp:routeOfAdministration
|
oral
|
gptkbp:sideEffect
|
gptkb:orthostatic_hypotension
constipation
blurred vision
weight gain
drowsiness
dry mouth
urinary retention
|
gptkbp:synonym
|
Nortrilen
|
gptkbp:UNII
|
BL03SY4LXB
|
gptkbp:usedFor
|
gptkb:major_depressive_disorder
peripheral neuropathy
chronic pain
migraine prophylaxis
|
gptkbp:bfsParent
|
gptkb:tricyclic_antidepressants
|
gptkbp:bfsLayer
|
6
|